Oltean S - Search Results

1

Bullock N, Oltean S. Bullock N, et al. Among authors: oltean s. J Pathol. 2017 Mar;241(4):437-440. doi: 10.1002/path.4846. Epub 2017 Feb 1. J Pathol. 2017. PMID: 27859253 Free PMC article.

2

WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.

Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR. Amin EM, et al. Among authors: oltean s. Cancer Cell. 2011 Dec 13;20(6):768-80. doi: 10.1016/j.ccr.2011.10.016. Cancer Cell. 2011. PMID: 22172722 Free PMC article.

3

SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.

Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO. Oltean S, et al. Biochem Soc Trans. 2012 Aug;40(4):831-5. doi: 10.1042/BST20120051. Biochem Soc Trans. 2012. PMID: 22817743 Review.

4

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.

Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Gammons MV, et al. Among authors: oltean s. Br J Cancer. 2014 Jul 29;111(3):477-85. doi: 10.1038/bjc.2014.342. Epub 2014 Jul 10. Br J Cancer. 2014. PMID: 25010863 Free PMC article.

5

Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S. Mavrou A, et al. Among authors: oltean s. Oncogene. 2015 Aug 13;34(33):4311-9. doi: 10.1038/onc.2014.360. Epub 2014 Nov 10. Oncogene. 2015. PMID: 25381816 Free PMC article.

6

Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion.

Bullock N, Potts J, Simpkin AJ, Koupparis A, Harper SJ, Oxley J, Oltean S. Bullock N, et al. Among authors: oltean s. J Clin Pathol. 2016 Feb;69(2):171-5. doi: 10.1136/jclinpath-2015-203125. Epub 2015 Oct 23. J Clin Pathol. 2016. PMID: 26500332 Free PMC article.

7

SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing.

Mavrou A, Oltean S. Mavrou A, et al. Among authors: oltean s. Pharmacol Res. 2016 May;107:276-281. doi: 10.1016/j.phrs.2016.03.013. Epub 2016 Mar 16. Pharmacol Res. 2016. PMID: 26995304 Free PMC article.

8

The VEGF-A exon 8 splicing-sensitive fluorescent reporter mouse is a novel tool to assess the effects of splicing regulatory compounds in vivo.

Stevens M, Star E, Lee M, Innes E, Li L, Bowler E, Harper S, Bates DO, Oltean S. Stevens M, et al. Among authors: oltean s. RNA Biol. 2019 Dec;16(12):1672-1681. doi: 10.1080/15476286.2019.1652522. Epub 2019 Aug 21. RNA Biol. 2019. PMID: 31432737 Free PMC article.

9

Pharmacology of Modulators of Alternative Splicing.

Bates DO, Morris JC, Oltean S, Donaldson LF. Bates DO, et al. Among authors: oltean s. Pharmacol Rev. 2017 Jan;69(1):63-79. doi: 10.1124/pr.115.011239. Pharmacol Rev. 2017. PMID: 28034912 Free PMC article. Review.

10

Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators.

Bates DO, Beazley-Long N, Benest AV, Ye X, Ved N, Hulse RP, Barratt S, Machado MJ, Donaldson LF, Harper SJ, Peiris-Pages M, Tortonese DJ, Oltean S, Foster RR. Bates DO, et al. Among authors: oltean s. Compr Physiol. 2018 Jun 18;8(3):955-979. doi: 10.1002/cphy.c170015. Compr Physiol. 2018. PMID: 29978898 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page